The relationship between HPV16 integration and cervical lesions

Aim: Cervical cancer is closely associated with persistent high-risk human papillomavirus (HR-HPV) infection. However, infections will persist in only 20% of the HR-HPV. The integration of the HPV DNA into the host DNA has been proposed as an early event and a risk factor for the progression of cervical lesions. Therefore, the purpose of this study is to evaluate the relationship between the physical status of HPV16 and the severity of cervical lesions based on both cytology and pathology results. Materials and Methods: A total of 150 patients with cervical lesions were enrolled in this study. All patients were HPV-positive, and corresponding pathology results were acquired by biopsy. HPV infection and the expression of HPV16 E2 and E6 forms were analyzed using multiplex-PCR, while the physical status of HPV16 was evaluated using the E2/E6 ratio. Results: The analysis of Spearman rank correlation showed that there were correlations between the integration ratio for HPV16 and the severity of cervical lesions based on both cytology and pathology results (both p <0.05). Conclusion: The integration ratio for HPV16 is closely associated with the severity of cervical lesions based on pathology and cytology and it is also an important risk factor for the persistence and progression of cervical lesions.

Human papillomavirus; Cervical lesions; Cervical cancer; HPV16; integration; E2 gene; E6 gene.

[1] Tellez L., Michelli E., Mendoza JA., Vielma S., Noguera ME., Callejas D., et al.: “Persistent infection with high-risk human papilloma viruses: cohort study, Merida, Venezuela”. Ecancermedicalscience, 2015, 9, 9579.

[2] De Brot L., Pellegrini B., Moretti ST., Carraro DM., Soares FA., Rocha RM., et al.: “Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix”. Cancer, 2017, 125, 138.

[3] Ho GY., Bierman R., Beardsley L., Chang CJ., Burk RD: “Natural history of cervicovaginal papillomavirus infection in young women”. N. Engl. J. Med., 1998, 338, 423.

[4] Iftner T., Wang L., Iftner A., Holz B., Haedicke-Jarboui J., Iftner N., et al.: “Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged >/=30 years using residual LBC ThinPrep specimens”. BMC Infect. Dis., 2016, 16, 72.

[5] Chen ZL., Su YJ., Zhang HL., Gu PQ., Gao LJ: “The role of the globular heads of the C1q receptor in HPV-16 E2-induced human cervical squamous carcinoma cell apoptosis via a mitochondriadependent pathway”. J. Transl. Med., 2014, 12, 286.

[6] Blackadar CB: “Historical review of the causes of cancer”.World J. Clin. Oncol., 2016, 7, 54.

[7] Jeon S., Lambert PF: “Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis”. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 1654.

[8] Nance KV: “Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening”. Drug Health Patient Saf., 2013, 5, 1.

[9] Sorbye S.W., Fismen S., Gutteberg T.J., Mortensen E.S., Skjeldestad F.E: “Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study”. BMJ Open, 2016, 6, e011981

[10]Liu Y., Lu Z., Xu R., Ke Y: “Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology”. Oncotarget, 2016, 7, 5852.

[11] Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I: “Human papillomavirus molecular biology and disease association”. Rev. Med. Virol., 2015, 25, 2.

[12] Han L., Maimaitiming T., Husaiyin S., Wang L., Wusainahong K., Ma C., et al.: “Comparative study of HPV16 integration in cervical lesions between ethnicities with high and low rates of infection with high-risk HPV and the correlation between integration rate and cervical neoplasia”. Exp. Ther. Med., 2015, 10, 2169.

[13] Zhao JW., Fang F., Guo Y., Zhu TL., Yu YY., Kong FF., et al.: “HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability”. J. Exp. Clin. Cancer Res., 2016, 35, 180.

[14]Nicolas-Parraga S., Gandini C., Pimenoff VN., Alemany L., de Sanjose S., Xavier Bosch F., et al.: “HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus”. Cancer Med., 2016, 5, 2909

[15] Nambaru L., Meenakumari B., Swaminathan R., Rajkumar T: “Prognostic significance of HPV physical status and integration sites in cervical cancer”. Asian Pac. J. Cancer Prev., 2009, 10, 355.

[16] Gonzalez-Losa M.D., Puerto-Solis M., Tenorio Ruiz J., RosadoLopez AI., Hau-Aviles O., Ayora-Talavera G., et al.: “Analysis of E2 gene integrity in HPV16 and HPV58 viruses isolated from women with cervical pathology”.Mem. Inst. Oswaldo Cruz., 2016, 111, 770.

[17] Mendes de Oliveira C., Levi JE: “The Biological Impact of Genomic Diversity in Cervical Cancer Development“. Acta Cytol., 2016, 60, 513. Epub 2016 Oct 22.

[18] Cook DA., Mei W., Smith LW., van Niekerk DJ., Ceballos K., Franco EL., et al.: “Comparison of the Roche cobas(R) 4800 and Digene Hybrid Capture(R) 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial”. BMC Cancer, 2015, 15, 968.

[19] Tao K., Yang J., Yang H., Guo ZH., Hu YM., Tan ZY., et al.: “Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions”. Diagn. Cytopathol., 2014, 42, 213.

[20] Zheng Y., Peng ZL., Lou JY., Wang H: “Detection of physical status of human papillomavirus 16 in cervical cancer tissue and SiHa cell line by multiplex real-time polymerase chain reaction”. Ai Zheng, 2006, 25, 373.

[21] Szostek S., Zawilinska B., Klimek M., Kosz-Vnenchak M: “HPV16 E6 polymorphism and physical state of viral genome in relation to the risk of cervical cancer in women from the south of Poland”. Acta Biochim Pol., 2017, 64, 143.

[22] Gallo G., Bibbo M., Bagella L., Zamparelli A., Sanseverino F., Giovagnoli MR., et al.: “Study of viral integration of HPV-16 in young patients with LSIL”. J. Clin. Pathol., 2003, 56, 532.

[23] Christiansen I.K., Sandve G.K., Schmitz M., Durst M., Hovig E.: “Transcriptionally active regions are the preferred targets for chromosomal HPV integration in cervical carcinogenesis”. PLoS One, 2015, 10, e0119566.